Navigation Links
PBS-Bio uncovers how Unibioscreen drug kills cancer
Date:3/9/2011

MESA, Ariz. March 8, 2011 Predictive Biomarker Sciences (PBS-Bio) has uncovered how the experimental drug UNBS1450, produced by Unibioscreen, kills cancer cells.

Previous studies have shown that over-activity of a gene known as MCL1 can cause cancer cells to grow out of control. PBS-Bio, which is owned in part by the non-profit, Phoenix-based Translational Genomics Research Institute (TGen), co-discovered that UNBS1450 effectively shuts off the gene and induces apoptosis, the cancer cell's normal process of cellular death.

"It's a very nice candidate drug," said Dr. Michael Bittner, a biologist and Principal Investigator of the PBS-Bio technology. Dr. Bittner said UNBS1450 is effective against MCL1 in very low dosages, which means it could potentially be delivered to patients with minimal side effects and low toxicity. MCL1 is prevalent in leukemia, non-small-cell lung cancer, as well as cancers of the prostate and pancreas.

"The presence of MCL1 can be used as a stratification, or predictive, biomarker to help determine which cancer patients are most likely to respond to UNBS1450," said Dr. Edward Smith, co-founder and CEO of PBS-Bio. This would be particularly beneficial, Dr. Smith said, in selecting patients to participate in clinical trials of UNBS1450, and ultimately in helping physicians decide who should be placed on the drug once it is approved for general use.

Steve Weitman, Chief Medical Officer for Unibioscreen, based in Brussels, Belgium, said Unibioscreen has high hopes for the drug UNBS1450.

"Thanks to the critical assistance we received from PBS-Bio, we at Unibioscreen feel confident now that we have a potential biomarker that can be used to facilitate the development of UNBS1450," Weitman said.

In October, Unibioscreen announced it had entered into an agreement with PBS-Bio to get a more in depth understanding of the mechanisms involved in UNBS1450 as a means of optimizing cancer-patient treatment.

To jump-start drug development, PBS-Bio's analysis helps pharmaceutical companies better understand how their drugs work, and identifies biomarkers that can help predict which patients will respond to treatment.

PBS-Bio is providing drug companies with unique real-time looks at how new therapeutics actually work over time within cellular pathways the so-called mechanisms of action.

UNBS1450 has been in Phase I clinical trials at hospitals in Belgium and the Netherlands. The drug is a hemi-synthetic derivative of a compound identified by Unibioscreen in the root bark of a plant called Calotropis procera. Pre-clinical tests showed that UNBS1450 is very effective against various tumor types with no adverse side effects.


'/>"/>

Contact: Dr. Edward Smith
edsmith@pbs-bio.com
602-418-9300
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. TGen partner, PBS-Bio, makes first breakthrough drug analysis
2. Georgia Dentist Uncovers Obscure Law That Helps Dental Patients With Severe Anxiety
3. New Research Uncovers Elusive Target of Antifungal Agent
4. Purdue-IU team uncovers potential prostate cancer marker
5. Research uncovers extensive natural recovery after spinal cord injury
6. UCLA team uncovers mechanism behind organ transplant rejection
7. Quest for designer bacteria uncovers a Spy
8. Research uncovers a secret society connecting through the Internet
9. Research Uncovers Clue to SIDS
10. New York Truck Driver Watching Porn Kills Mother, Appalls Personal Injury Lawyers Such As David Perecman
11. Cognitive Skills May Shrink With Tamoxifen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... WASHINGTON, DC (PRWEB) , ... March 28, 2017 , ... ... and Dr. Toni Bark , WHAT: , Medical doctors and PhD scientists will speak ... have written to President Trump in support of an independent vaccine safety commission. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... The ... MHA, FRBMA, has begun to serve as its new executive director. Mr. Still was ... Executive Search Committee. , “Bob, as he is known to our members, has ...
(Date:3/28/2017)... Calif. (PRWEB) , ... March 28, 2017 , ... ... its leading physicians, Paul Yost, will begin serving as new board chair for ... this month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology ... two biometric time and attendance tracking products: the new NCheck Cloud Bio Attendance ... Bio Attendance uses biometric face recognition to enable users to check in and ...
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER TOLEDO Process Analytics ... power plant water and steam. , Chlorides and sulfates cause pitting and stress ... extensive maintenance and unplanned shutdowns. Monitoring these ions at low ppb levels has ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Calif. , March 27, 2017  Cryoport, Inc. ... that it intends to offer shares of common stock ... registration statement on file with the Securities and Exchange ... and other conditions, and there can be no assurance ... completed, or as to the actual size or terms ...
(Date:3/27/2017)... N.Y. , March 27, 2017 To mark ... U.S.A. , Inc., a leader in digital imaging solutions, ... Expo East convention, held at New York,s ... 2017. Save Your Vision Month, sponsored by the American Optometric ... and the importance of receiving comprehensive eye exams. In recognition ...
(Date:3/27/2017)... and VANCOUVER, British Columbia, March 27, 2017 /PRNewswire/ ... (the "Company" or "Sophiris"), a clinical late-stage biopharmaceutical ... patients with urological diseases, today reported fourth quarter ... corporate highlights. Key Corporate Highlights: ... Development for Localized Prostate Cancer. During 2016, the ...
Breaking Medicine Technology: